2024-04-11 11:12:32 ET
More on Pfizer, Teva, etc.
- Teva Pharmaceutical Industries: Potential Outweighs Concerns
- Pfizer: Attractive Valuation And A Strong Pipeline Mitigate Patent Cliff Concerns
- Pfizer Inc. (PFE) Leerink Partners Global Biopharma Conference 2024 - (Transcript)
- Teva confirms efficacy in late-stage trial of its migraine treatment for adult Chinese patients
- Pfizer RSV shot meets key goal in trial of high-risk adults under age 60
Read the full article on Seeking Alpha
For further details see:
Pfizer unit to settle Effexor XR antitrust claims in $39M deal